MELAS syndrome

Last updated
Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes
A computed tomography brain scan showing bilateral basal ganglia calcification.jpg
Basal ganglia calcification, cerebellar atrophy, increased lactate; a CT image of a person diagnosed with MELAS
Specialty Neurology   OOjs UI icon edit-ltr-progressive.svg
Frequency1 in 4000 [1]

MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) is one of the family of mitochondrial diseases, which also include MIDD (maternally inherited diabetes and deafness), MERRF syndrome, and Leber's hereditary optic neuropathy. It was first characterized under this name in 1984. [2] A feature of these diseases is that they are caused by defects in the mitochondrial genome which is inherited purely from the female parent. [3] The most common MELAS mutation is one in mitochondrial DNA (mtDNA) referred to as m.3243A>G. [4]

Contents

Signs and symptoms

MELAS is a condition that affects many of the body's systems, particularly the brain and nervous system (encephalo-) and muscles (myopathy). As such, it is commonly referred to as a mitochondrial encephalomyopathy, due to the co-occurrence of these pathologies. In most cases, the signs and symptoms of this disorder appear in childhood following a period of normal development. [5] Children with MELAS often have normal early psychomotor development until the onset of symptoms between 2 and 10 years old. Though less common, infantile onset may occur and may present as failure to thrive, growth retardation and progressive deafness. Onset in older children typically presents as recurrent attacks of a migraine-like headache, anorexia, vomiting, and seizures. Children with MELAS are also frequently found to have short stature. [1]

Most people with MELAS have a buildup of lactic acid in their bodies, a condition called lactic acidemia. Increased acidity in the blood can lead to vomiting, abdominal pain, extreme tiredness (fatigue), muscle weakness, loss of bowel control, and difficulty breathing. Less commonly, people with MELAS may experience involuntary muscle spasms (myoclonus), impaired muscle coordination (ataxia), hearing loss, heart and kidney problems, diabetes, epilepsy, and hormonal imbalances. [6] Lactic acidemia also promotes mitochondrial dysfunction, one of the hallmarks of MELAS pathophysiology. [4]

Differential diagnosis

The presentation of some cases is similar to that of Kearns–Sayre syndrome. [7] [1]

Myoclonus epilepsy associated with ragged red fibers (MERRF) may be confused with MELAS as they both involve seizures, mental deterioration, and myopathy with ragged red fibers on biopsy. MERRF patients may also have hearing loss, visual disturbance secondary to optic atrophy, and short stature. The characteristic myoclonic seizure in MERRF may help to narrow diagnosis, but genetic testing should be considered to distinguish the two conditions. [1]

Leigh syndrome may also present with progressive neurological deterioration, seizures, and vomiting, mainly in young children. [1]

Genetics

Muscle biopsy of a person diagnosed with MELAS but carrying no known mutation. (a) Modified Gomori trichrome stain showing several ragged red fibers (arrowhead). (b) Cytochrome c oxidase stain showing Type-1 lightly stained and Type II fibers, darker fibers, and a few fibers with abnormal collections of mitochondria (arrowhead). Note cytochrome c oxidase negative fibers as usually seen in mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS). (c) Succinate dehydrogenase staining showing a few ragged blue fibers and intense staining in the mitochondria of the blood vessels (arrow). (d) Electron microscopy showing abnormal collection of mitochondria with paracrystalline inclusions (arrowhead), osmiophilic inclusions (large arrowhead) and mitochondrial vacuoles (small arrowhead). Modified Gomori trichrome stain showing several ragged red fibers.jpg
Muscle biopsy of a person diagnosed with MELAS but carrying no known mutation. (a) Modified Gomori trichrome stain showing several ragged red fibers (arrowhead). (b) Cytochrome c oxidase stain showing Type-1 lightly stained and Type II fibers, darker fibers, and a few fibers with abnormal collections of mitochondria (arrowhead). Note cytochrome c oxidase negative fibers as usually seen in mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS). (c) Succinate dehydrogenase staining showing a few ragged blue fibers and intense staining in the mitochondria of the blood vessels (arrow). (d) Electron microscopy showing abnormal collection of mitochondria with paracrystalline inclusions (arrowhead), osmiophilic inclusions (large arrowhead) and mitochondrial vacuoles (small arrowhead).

MELAS is mostly caused by mutations in the genes in mitochondrial DNA, but it can also be caused by mutations in the nuclear DNA. [6]

NADH dehydrogenase

Some of the genes (MT-ND1, MT-ND5) affected in MELAS encode proteins that are part of NADH dehydrogenase (also called complex I) in mitochondria, that helps convert oxygen and simple sugars to energy. [9]

Transfer RNAs

Other genes (MT-TH, MT-TL1, and MT-TV) encode mitochondrial specific transfer RNAs (tRNAs). [10]

Mutations in the mitochondrial MT-TL1 gene cause more than 80 percent of all cases of MELAS. This gene encodes a tRNA specific to the amino acid Leucine. These mutations impair the ability of mitochondria to make proteins, use oxygen, and produce energy. Researchers have not determined how changes in mitochondrial DNA lead to the specific signs and symptoms of MELAS. They continue to investigate the effects of mitochondrial gene mutations in different tissues, particularly in the brain. [11]

Inheritance

This condition is inherited in a mitochondrial pattern, which is also known as maternal inheritance and heteroplasmy. This pattern of inheritance applies to genes contained in mitochondrial DNA. Because egg cells, but not sperm cells, contribute mitochondria to the developing embryo, only females pass mitochondrial conditions to their children. Mitochondrial disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass mitochondrial traits to their children. In most cases, people with MELAS inherit an altered mitochondrial gene from their mother. Less commonly, the disorder results from a new mutation in a mitochondrial gene and occurs in people with no family history of MELAS.[ citation needed ]

Although first recognised and described in 1984 the condition occurred well before that date. Josiah Wedgwood gave detailed description of this illness in his youngest daughter, Mary Ann Wedgwood (1778–1786). [12] Her illness may provide a link to the illnesses that afflicted her elder brother, Thomas Wedgwood, her eldest sister Susannah Darwin, and Susannah's second son, the famous naturalist, Charles Darwin. The illnesses that afflicted the Wedgwood-Darwin families have a well defined matrilineal inheritance pattern.

Diagnosis

Genetic testing for the m.3243A>G mutation in mitochondrial DNA is commonly used to isolate the diagnosis of MELAS syndrome from other mitochondrial disorders. [13] This mutation is an adenine to guanine point mutation at base pair 3,243 in the mitochondrial genome. A minimum amount of mtDNA must be mutated to generate the MELAS phenotype, known as the "threshold effect". [14] Due to mitochondrial heteroplasmy, urine and blood testing is preferable to blood alone. [1] PCR and ARMS-PCR are commonly used, reliable, rapid, and cost-effective techniques for the diagnosis of MELAS. [11]

Magnetic-resonance imaging (MRI) is a common imaging test used to identify the presence of stroke-like lesions. These lesions are multifocal infarct-like areas of cortical edema in different stages of ischemic evolution, yet do not commonly conform to any known vascular territory, distinguishing them from a stroke. Initial lesions often occur in the occipital or parietal lobes with eventual involvement of the cerebellum, cerebral cortex, basal ganglia, and thalamus. [15] The occipital lobe is thought to be a region prone to stroke-like lesions due to the high energy requirements of the visual cortex. [16]

Lactate levels are often elevated in serum and cerebrospinal fluid. Magnetic resonance spectroscopy (MRS) may show an elevated lactate peak in affected and even unaffected brain areas. Muscle biopsy shows ragged red fibers. However, genetic evaluation should be done first, which eliminates the need for muscle biopsy in most cases. Diagnosis may be molecular or clinical: [11]

Sensorineural hearing loss and mitochondrial diabetes are common features. [4] Eyes may have a distinctive speckled pigment in the retina, referred to as a maculopathy. Family members may present differently.

Treatment

There is no curative treatment. The disease remains progressive and fatal. [17] [18] Current treatment is aimed towards improving mitochondrial function through both pharmacological and non-pharmacological methods.

Multiple case studies [19] [20] [21] have suggested that implementation of the Ketogenic diet may help reduce the incidence of stroke-like episodes associated with MELAS, one of the most common clinical features. [4] Ketogenic diet therapy helps with the clearance of reactive-oxygen species (ROS), which commonly accumulate and harm the mitochondria in MELAS.

Other supplementation treatments have been studied:

Epidemiology

The exact incidence of MELAS is unknown. [26] It is one of the more common conditions in a group known as mitochondrial diseases. [26] Nation-wide studies from Japan and Finland have suggested a prevalence of 1 in 500,000 people [27] and 16 in 100,000 people, [28] respectively. Together, mitochondrial diseases occur in about 1 in 4,000 people. [26]

See also

References

  1. 1 2 3 4 5 6 Pia S, Lui F (2020). "Melas Syndrome". Statpearls. Treasure Island (FL): StatPearls Publishing. PMID   30422554. CC-BY icon.svg Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
  2. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP (October 1984). "Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome". Annals of Neurology. 16 (4): 481–488. doi:10.1002/ana.410160409. PMID   6093682. S2CID   41412358.
  3. Hirano M, Pavlakis SG (January 1994). "Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts". Journal of Child Neurology. 9 (1): 4–13. doi:10.1177/088307389400900102. PMID   8151079. S2CID   31329972.
  4. 1 2 3 4 El-Hattab, Ayman W.; Adesina, Adekunle M.; Jones, Jeremy; Scaglia, Fernando (2015-09-01). "MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options" . Molecular Genetics and Metabolism. SI:Therapy. 116 (1): 4–12. doi:10.1016/j.ymgme.2015.06.004. ISSN   1096-7192. PMID   26095523.
  5. MELAS syndrome at NLM Genetics Home Reference
  6. 1 2 Valiente-Pallejà, Alba; Tortajada, Juan; Bulduk, Bengisu K.; Vilella, Elisabet; Garrabou, Glòria; Muntané, Gerard; Martorell, Lourdes (2022). "Comprehensive summary of mitochondrial DNA alterations in the postmortem human brain: A systematic review". eBioMedicine. 76. doi:10.1016/j.ebiom.2022.103815. PMC   8790490 . PMID   35085849.
  7. Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, DeVivo DC, et al. (1992). "Melas: an original case and clinical criteria for diagnosis". Neuromuscular Disorders. 2 (2): 125–135. doi:10.1016/0960-8966(92)90045-8. PMID   1422200. S2CID   45634693.
  8. Abu-Amero KK, Al-Dhalaan H, Bohlega S, Hellani A, Taylor RW (October 2009). "A patient with typical clinical features of mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) but without an obvious genetic cause: a case report". Journal of Medical Case Reports. 3: 77. doi: 10.1186/1752-1947-3-77 . PMC   2783076 . PMID   19946553.
  9. Tranchant C, Anheim M (2016). "Movement disorders in mitochondrial diseases". Revue Neurologique. 172 (8–9): 524–529. doi:10.1016/j.neurol.2016.07.003. PMID   27476418.
  10. Yarham, John W.; Elson, Joanna L.; Blakely, Emma L.; McFarland, Robert; Taylor, Robert W. (2010). "Mitochondrial tRNA mutations and disease" . WIREs RNA. 1 (2): 304–324. doi:10.1002/wrna.27. ISSN   1757-7012. PMID   21935892.
  11. 1 2 3 Bulduk, B. K., Kiliç, H. B., Bekircan-Kurt, C. E., Haliloğlu, G., Erdem Özdamar, S., Topaloğlu, H., & Kocaefe, Y. Ç. (2020). A Novel Amplification-Refractory Mutation System-PCR Strategy to Screen MT-TL1 Pathogenic Variants in Patient Repositories. Genetic testing and molecular biomarkers, 24(3), 165–170. https://doi.org/10.1089/gtmb.2019.0079
  12. Hayman, John; Pavlakis, Steven; Finsterer, Josef (2022-02-17). "Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) in the 18th Century: Mitochondrial Disorders Are Not of Recent Origin". Cureus. 14 (2): e22314. doi: 10.7759/cureus.22314 . ISSN   2168-8184. PMC   8856639 . PMID   35198337.
  13. Na, Ji-Hoon; Lee, Young-Mock (2024-11-28). "Diagnosis and Management of Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes Syndrome". Biomolecules. 14 (12): 1524. doi: 10.3390/biom14121524 . ISSN   2218-273X. PMC   11672891 . PMID   39766231.
  14. Schapira, Anthony HV (2006-07-01). "Mitochondrial disease" . The Lancet. 368 (9529): 70–82. doi:10.1016/S0140-6736(06)68970-8. ISSN   0140-6736. PMID   16815381.
  15. Khasminsky, Vadim; Auriel, Eitan; Luckman, Judith; Eliahou, Ruth; Inbar, Edna; Pardo, Keshet; Landau, Yuval; Barnea, Rani; Mermelstein, Maor; Shelly, Shahar; Naftali, Jonathan; Peretz, Shlomi (August 2023). "Clinicoradiologic Criteria for the Diagnosis of Stroke-like Episodes in MELAS". Neurology Genetics. 9 (4): e200082. doi:10.1212/NXG.0000000000200082. PMC   10323819 . PMID   37426458.
  16. Wong-Riley, Margaret (July 2010). "Energy metabolism of the visual system". Eye and Brain. 2: 99–116. doi: 10.2147/EB.S9078 . ISSN   1179-2744. PMC   3515641 . PMID   23226947.
  17. Quinn NM, Stone G, Brett F, Caro-Dominguez P, Neylon O, Lynch B (September 2016). "MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke) - a Diagnosis Not to be Missed". Irish Medical Journal. 109 (8): 455. PMID   28124854.
  18. Muñoz-Guillén N, León-López R, Ferrer-Higueras MJ, Vargas-Vaserot FJ, Dueñas-Jurado JM (August 2009). "[Arreflexic coma and MELAS syndrome]" [Arreflexic coma and MELAS syndrome]. Revista Clinica Espanola (in Spanish). 209 (7): 337–341. doi:10.1016/s0014-2565(09)71818-1. PMID   19709537.
  19. Kang, Hoon-Chul; Lee, Young-Mock; Kim, Heung Dong; Lee, Joon Soo; Slama, Abdelhamid (2007). "Safe and Effective Use of the Ketogenic Diet in Children with Epilepsy and Mitochondrial Respiratory Chain Complex Defects" . Epilepsia. 48 (1): 82–88. doi:10.1111/j.1528-1167.2006.00906.x. ISSN   1528-1167. PMID   17241212.
  20. Na, Ji-Hoon; Kim, Heung-Dong; Lee, Young-Mock (2020-01-01). "Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction". Therapeutic Advances in Neurological Disorders. 13: 1756286419897813. doi:10.1177/1756286419897813. ISSN   1756-2864. PMC   7005978 . PMID   32082420.
  21. Zweers, Heidi; van Wegberg, Annemiek M. J.; Janssen, Mirian C. H.; Wortmann, Saskia B. (2021-07-03). "Ketogenic diet for mitochondrial disease: a systematic review on efficacy and safety". Orphanet Journal of Rare Diseases. 16 (1): 295. doi: 10.1186/s13023-021-01927-w . ISSN   1750-1172. PMC   8254320 . PMID   34217336.
  22. Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA (February 2007). "Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders". Muscle & Nerve. 35 (2): 235–242. doi:10.1002/mus.20688. PMID   17080429. S2CID   28962906.
  23. Koga Y, Akita Y, Nishioka J, Yatsuga S, Povalko N, Katayama K, Matsuishi T (2007). "MELAS and L-arginine therapy". Mitochondrion. 7 (1–2): 133–139. doi:10.1016/j.mito.2006.11.006. PMID   17276739.
  24. Ohsawa, Yutaka; Hagiwara, Hiroki; Nishimatsu, Shin-ichiro; Hirakawa, Akihiro; Kamimura, Naomi; Ohtsubo, Hideaki; Fukai, Yuta; Murakami, Tatsufumi; Koga, Yasutoshi; Goto, Yu-ichi; Ohta, Shigeo; Sunada, Yoshihide (May 2019). "Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial". Journal of Neurology, Neurosurgery & Psychiatry. 90 (5): 529–536. doi:10.1136/jnnp-2018-317964. ISSN   0022-3050. PMC   6581075 . PMID   29666206.
  25. Schaffer, Stephen; Kim, Ha Won (2018-05-01). "Effects and Mechanisms of Taurine as a Therapeutic Agent". Biomolecules & Therapeutics. 26 (3): 225–241. doi:10.4062/biomolther.2017.251. ISSN   2005-4483. PMC   5933890 . PMID   29631391.
  26. 1 2 3 "MELAS". Genetics Home Reference. December 2013. Retrieved 11 April 2017.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  27. Yatsuga, Shuichi; Povalko, Nataliya; Nishioka, Junko; Katayama, Koju; Kakimoto, Noriko; Matsuishi, Toyojiro; Kakuma, Tatsuyuki; Koga, Yasutoshi (May 2012). "MELAS: A nationwide prospective cohort study of 96 patients in Japan" . Biochimica et Biophysica Acta (BBA) - General Subjects. 1820 (5): 619–624. doi:10.1016/j.bbagen.2011.03.015. PMID   21443929.
  28. Majamaa, Kari; Moilanen, Jukka S.; Uimonen, Seija; Remes, Anne M.; Salmela, Pasi I.; Kärppä, Mikko; Majamaa-Voltti, Kirsi A.M.; Rusanen, Harri; Sorri, Martti; Peuhkurinen, Keijo J.; Hassinen, Ilmo E. (August 1998). "Epidemiology of A3243G, the Mutation for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes: Prevalence of the Mutation in an Adult Population". The American Journal of Human Genetics. 63 (2): 447–454. doi:10.1086/301959. PMC   1377301 . PMID   9683591.